Methods	Six-week randomised, double-blind, multicentre study.
Participants	In- and outpatients fulfilling DSM-IV criteria for major depressive episode without psychotic features, with a score between 18 and 26 on the HDRS-17. Age range: 40-65 years. Exclusion criteria: past histrory of hypersensitivity, to fluoxetine or maprotiline, history or presence of gastrointestinal, liver or kidney disease, pregnancy, lactation, history of seizures or serious brain damage, current evidence of clinically important cardiovascular or hematopoietic disease, urinary retention or glaucoma with closed angle, abnormal findings in physical examination, laboratory tests and ECG at admission, evidence of substance use disorder within the past 6 months or currently, use of MAOI within 2 weeks before the study
Interventions	Fluoxetine: 50 participants. Maprotiline : 48 participants. Fluoxetine dose range: 20-40 mg/day. Maprotiline dose range: 75-150 mg/day.
Outcomes	Hamilton Rating Scale for Depression, CGI
Notes	Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear